Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

NCT02792699 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

311

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: ABP 798
DRUG: Rituximab (US)
DRUG: Rituximab (EU)

Sponsor

Amgen